Filing Flows › Comparisons › AMRN vs SPRY
Amarin vs ARS Pharmaceuticals: AMRN and SPRY compared
Amarin is the larger company: $39.5M of revenue in its latest quarter (Q3 2026) against $37.7M for ARS Pharmaceuticals (Q3 2026). ARS Pharmaceuticals is growing faster (+16% against -20% a year earlier). Amarin is more profitable, with an operating margin of -6.0% against -90.6%.
Where the money goes: AMRN and SPRY
Amarin (AMRN) · Q3 2026
Amarin, Q3 2026: revenue $39.5M (-20% year over year), operating margin -6.0%, net earnings $245K, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
ARS Pharmaceuticals (SPRY) · Q3 2026
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
| Amarin (AMRN) | ARS Pharmaceuticals (SPRY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $39.5M | $37.7M |
| Revenue growth, Y/Y | -20% | +16% |
| Operating margin | -6.0% | -90.6% |
| Net earnings | $245K | −$35.6M |
| Net margin | 0.6% | -94.4% |
| Operating cash flow | $9.2M | −$33.7M |
Where the revenue comes from
Amarin
- Product: $36.9M (93%)
- Licensing and Royalty: $2.7M (7%)
ARS Pharmaceuticals
- Product: $33.4M (89%)
- Revenue Under Supply Agreements: $2.6M (7%)
- Revenue Under Collaboration Agreements: $1.7M (4%)
Questions
Which is bigger, Amarin or ARS Pharmaceuticals?
Amarin is the larger company: $39.5M of revenue in its latest quarter (Q3 2026) against $37.7M for ARS Pharmaceuticals (Q3 2026).
Is Amarin or ARS Pharmaceuticals growing faster?
ARS Pharmaceuticals is growing faster (+16% against -20% a year earlier).
Which is more profitable, Amarin or ARS Pharmaceuticals?
Amarin is more profitable, with an operating margin of -6.0% against -90.6%.
More: Amarin earnings · how Amarin makes money · ARS Pharmaceuticals earnings · how ARS Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 28, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.